Oryzon Genomics Full Year 2024 Earnings: €0.057 loss per share (vs €0.055 loss in FY 2023)
Oryzon Genomics (BME:ORY) Full Year 2024 Results
Key Financial Results
- Net loss: €3.67m (loss widened by 9.3% from FY 2023).
- €0.057 loss per share (further deteriorated from €0.055 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Oryzon Genomics Earnings Insights
Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.
Performance of the market in Spain.
The company's shares are down 28% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Oryzon Genomics you should be aware of.
If you're looking to trade Oryzon Genomics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BME:ORY
Oryzon Genomics
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.
High growth potential with imperfect balance sheet.
